Year None20232022202120202019201820172016 Feb 04, 2021 Evaxion Biotech Announces Pricing of Initial Public Offering Jan 08, 2021 Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities Dec 23, 2020 Evaxion Biotech doses first patient in Phase I/IIa melanoma trial of cancer vaccine EVX-02 in combination with checkpoint inhibitors Dec 17, 2020 Evaxion Biotech appoints Marianne Søgaard as Chairwoman Dec 09, 2020 Evaxion Biotech announces publication in Nature Communications describing improved selection of immunotherapy targets Dec 09, 2020 EU Boosts Evaxion’s Artificial Intelligence Vaccine Research Oct 22, 2020 SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology Oct 02, 2020 Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics Jul 22, 2020 Evaxion Biotech among the top 16 global companies using artificial intelligence to revolutionize drug discovery, according to experts from Frost & Sullivan Dec 20, 2019 Evaxion raises nearly $17 million in Q4 Oct 30, 2019 Glenn S. Vraniak Joins Evaxion as CFO Apr 05, 2019 Evaxion announces dosing of first patient Jan 09, 2019 Evaxion Granted Approval for Clinical Trial Application and Investigation Medicinal Product Dossier Feb 28, 2018 Evaxion Biotech Expands Board of Directors with Appointment of Infectious Disease Expert Steven Projan Dec 05, 2017 Evaxion Awarded $3M Innovation Fund Denmark Grant for Development of Personalized Cancer Therapies Nov 01, 2017 Evaxion Biotech Awarded €1,6M Eurostars Grant Jul 01, 2017 Lars Wegner Joins Evaxion Biotech Jul 16, 2016 European CEO names Evaxion CEO Niels Møller Best CEO in the Vaccination Industry 2016 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 51 - 68 of 68
Jan 08, 2021 Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities
Dec 23, 2020 Evaxion Biotech doses first patient in Phase I/IIa melanoma trial of cancer vaccine EVX-02 in combination with checkpoint inhibitors
Dec 09, 2020 Evaxion Biotech announces publication in Nature Communications describing improved selection of immunotherapy targets
Oct 22, 2020 SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology
Oct 02, 2020 Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics
Jul 22, 2020 Evaxion Biotech among the top 16 global companies using artificial intelligence to revolutionize drug discovery, according to experts from Frost & Sullivan
Jan 09, 2019 Evaxion Granted Approval for Clinical Trial Application and Investigation Medicinal Product Dossier
Feb 28, 2018 Evaxion Biotech Expands Board of Directors with Appointment of Infectious Disease Expert Steven Projan
Dec 05, 2017 Evaxion Awarded $3M Innovation Fund Denmark Grant for Development of Personalized Cancer Therapies